Provided by Tiger Fintech (Singapore) Pte. Ltd.

IceCure Medical Ltd.

1.41
+0.03002.17%
Mar 14 15:48 EST
Volume:161.97K
Turnover:228.20K
Market Cap:79.76M
PE:-4.92
High:1.44
Open:1.38
Low:1.38
Close:1.38
1D
5D
D
W
M
Q
Y
1m
5m
10m
15m
30m
1h
2h
More
1D
5D
D
W
M
Q
Y
1m
5m
10m
15m
30m
1h
2h
Loading ...

IceCure Medical’s Cryoablation Shows Higher Patient Satisfaction in Japan Study

TIPRANKS
·
10 Mar

Breast Cancer Patients who Underwent IceCure's ProSense® Cryoablation in Japan Reported Significantly Higher Satisfaction than Patients who Underwent Standard of Care Surgery

PR Newswire
·
10 Mar

IceCure Medical files for regulatory approval of cryoablation system in Israel

TIPRANKS
·
24 Feb

Icecure Submits Filing for Regulatory Approval of Its Next-Generation Xsense™ Cryoablation System in Israel

THOMSON REUTERS
·
24 Feb

IceCure Submits Filing for Regulatory Approval of its Next-Generation XSense™ Cryoablation System in Israel

PR Newswire
·
24 Feb

IceCure Medical Ltd's (NASDAQ:ICCM) Profit Outlook

Simply Wall St.
·
18 Feb

IceCure Medical Awaits FDA Decision as ProSense® Gains Attention

TIPRANKS
·
04 Feb

IceCure's ProSense® in the Spotlight at Society of Interventional Oncology (SIO) Annual Meeting: Award Winning Abstract and Hands-On Training for Breast Cryoablation as Medical Community Anticipates FDA's Market Authorization Decision

PR Newswire
·
04 Feb

IceCure Medical Seeks to Expand in China with ProSense® Cryoablation System

TIPRANKS
·
27 Jan

Icecure Files for Regulatory Approval of Prosense® Cryoablation System in China

THOMSON REUTERS
·
27 Jan

IceCure Files for Regulatory Approval of ProSense® Cryoablation System in China

PR Newswire
·
27 Jan

Icecure Medical : Entered Into Equity Distribution Agreement With Maxim Group Llc

THOMSON REUTERS
·
13 Jan

Icecure Medical Ltd: May Offer, Sell Ordinary Shares of up to $13.96 Mln From Time to Time

THOMSON REUTERS
·
13 Jan

IceCure Medical Reports Strong Growth and Anticipates FDA Approval in 2025

TIPRANKS
·
13 Jan

IceCure Medical CEO Issues Letter to Shareholders & Reports Increase of 42% in ProSense® Sales for 2024 in North America

PR Newswire
·
13 Jan

The five-year returns have been enviable for IceCure Medical (NASDAQ:ICCM) shareholders despite underlying losses increasing

Simply Wall St.
·
08 Jan

If the download button clicks without skipping, click on the top right menu and select "Open in Browser."